Bank of Stockton Increases Stock Position in Sanofi (NASDAQ:SNY)

Bank of Stockton raised its position in shares of Sanofi (NASDAQ:SNY) by 6.0% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 6,251 shares of the company’s stock after purchasing an additional 352 shares during the period. Bank of Stockton’s holdings in Sanofi were worth $301,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Franklin Resources Inc. raised its position in shares of Sanofi by 13.1% in the 3rd quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock worth $208,106,000 after purchasing an additional 395,744 shares during the last quarter. Natixis Advisors LLC raised its position in shares of Sanofi by 4.1% in the 3rd quarter. Natixis Advisors LLC now owns 2,874,193 shares of the company’s stock worth $165,640,000 after purchasing an additional 114,133 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Sanofi by 20.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock worth $133,172,000 after purchasing an additional 399,301 shares during the last quarter. DAVENPORT & Co LLC raised its position in shares of Sanofi by 40.7% in the 4th quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock worth $110,715,000 after purchasing an additional 664,455 shares during the last quarter. Finally, Jennison Associates LLC raised its position in shares of Sanofi by 938.0% in the 3rd quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock worth $109,753,000 after purchasing an additional 1,720,972 shares during the last quarter. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on SNY. StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Two analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, Sanofi has an average rating of “Buy” and an average target price of $60.00.

Sanofi Price Performance

NASDAQ SNY opened at $54.13 on Friday. Sanofi has a one year low of $45.22 and a one year high of $58.97. The stock has a 50-day moving average of $50.79 and a 200 day moving average of $52.50. The company has a market capitalization of $137.37 billion, a price-to-earnings ratio of 21.74, a PEG ratio of 1.00 and a beta of 0.57. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. On average, sell-side analysts forecast that Sanofi will post 4.36 EPS for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.